Walden Biosciences
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1 Kendall Sq Ste 7102, Cambridge, Massac...Website
www.waldenbiosciences.comRevenue
$8.5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Walden Biosciences
Walden Biosciences is a biotech company focused on transforming the treatment of kidney disease through innovative, disease-modifying therapies. They are currently enrolling participants for a Phase 2 clinical research study aimed at individuals with rare chronic kidney diseases. The company is dedicated to developing new therapies that directly target kidney conditions, demonstrating a commitment to improving the lives of patients affected by these diseases. Their pipeline includes promising treatments such as WAL0921 and WAL0623.Explore more
Walden Biosciences Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Walden Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Walden Biosciences recently announced quarterly report
Product Launch: Get notified when Walden Biosciences launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Walden Biosciences has recently received funding, and reach out quickly before it becomes old news!
Walden Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Walden Biosciences had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Walden Biosciences
Check out if Walden Biosciences is spiking on competitors!
Funding: Get notified immidiatlly once Walden Biosciences has new funding data
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Walden Biosciences as Masked Content
Find more new buyers
Compare Similar Companies to Walden Biosciences
Compare insights from companies similar to Walden Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Walden Biosciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Walden Biosciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Walden Biosciences.
Walden Biosciences financials insights
Gather financial insights about Walden Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$51M
Walden Biosciences Tech Stack
A closer look at the technologies used by Walden Biosciences
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Project
Research & Development, Medical Research, Pharmaceuticals, Clinical Operations
Open Position
Executive Move
Board of Directors
Walden Biosciences News & Media
Walden Biosciences Appoints Howard Mayer, M.D. to Board of Directors
Veteran Leader Brings Extensive Expertise in Rare Disease, including Renal Disease, and a Track Record of Regulatory Success with Orphan Diseases and Breakthrough Therapy Designations Veteran Leader Brings Extensive Expertise in Rare Disease, including Renal Disease, and a Track Record of Regulatory Success with Orphan Diseases and Breakthrough Therapy DesignationsWalden Biosciences Highlights 2024 Accomplishments and 2025 Priorities
Fully Enrolled Second Cohort in Phase 2 Basket Study of WAL0921 In Chronic Kidney DiseaseWalden Biosciences Fully Enrolls First Cohort in Phase 2 Basket Study of WAL0921 in Chronic Kidney Diseases
Expects Topline Results from First Multiple Ascending Dose Cohort by Year-end 2024 and to Initiate Rare Kidney Disease Cohorts in Early 2025 Expects Topline Results from First Multiple Ascending Dose Cohort by Year-end 2024 and to Initiate Rare Kidney Disease Cohorts in Early 2025Walden Biosciences Announces Research Collaboration with World Renowned Genetic Epidemiologist to Advance Work on Causal Role of suPAR in Chronic Kidney Disease
Study to further understand the established role that suPAR plays in causing kidney disease Study to further understand the established role that suPAR plays in causing kidney disease
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Walden Biosciences
Sign Up For FreeTo access detailed company insights
Walden Biosciences is a biotech company focused on transforming the treatment of kidney disease through innovative, disease-modifying therapies. They are currently enrolling participants for a Phase 2 clinical research study aimed at individuals with rare chronic kidney diseases. The company is dedicated to developing new therapies that directly ta... Read More
